Neoclone Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- Neoclone Biotechnology's estimated annual revenue is currently $930k per year.
- Neoclone Biotechnology's estimated revenue per employee is $155,000
Employee Data
- Neoclone Biotechnology has 6 Employees.
- Neoclone Biotechnology grew their employee count by 0% last year.
Neoclone Biotechnology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Phage Technologies | Reveal Email/Phone |
Neoclone Biotechnology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Neoclone Biotechnology?
NeoClone produces high-quality monoclonal antibody products for the biotechnology and research markets. In addition to generating monoclonals through the traditional fusion technology NeoClone holds exclusive license to the ABL-MYC retroviral transformation system, a technique that produces monoclonal antibodies -- "NeoClone®"-brand or "NeoAb®" antibodies -- in an accelerated time and with cost savings. This allows NeoClone to provide custom antibodies faster and more cost effective.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 6 | -25% | $2.3M |
#2 | $0.7M | 6 | -62% | N/A |
#3 | $0.4M | 6 | N/A | N/A |
#4 | $0.4M | 6 | N/A | N/A |
#5 | $0.4M | 6 | N/A | N/A |